Overview

• AMN Healthcare Q3 revenue of $634 mln beats analyst expectations despite 8% yr/yr decline

• Adjusted EPS of $0.39 for Q3 beats analyst expectations, down 36% yr/yr

• Company refinanced senior notes and extended credit facility, enhancing financial flexibility

Outlook

• Company expects Q4 revenue between $715 mln and $730 mln

• Nurse and Allied Solutions revenue expected to rise 1-3% year-over-year

• Technology and Workforce Solutions revenue projected to decline 14-16% year-over-year

Result Drivers

• REVENUE GUIDANCE EXCEEDED - Co's Nurse and Allied Solutions and Physician and Leadership Solutions segments performed better than expectations, contributing to revenue exceeding guidance

• SG&A MANAGEMENT - Effective management of SG&A expenses resulted in a higher-than-expected adjusted EBITDA margin

• STAFFING ORDERS REBOUND - Co reports a rebound in staffing orders and higher winter order volume

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 3 "strong buy" or "buy", 5 "hold" and 1 "sell" or "strong sell"

• The average consensus recommendation for the healthcare facilities & services peer group is "buy."

• Wall Street's median 12-month price target for AMN Healthcare Services Inc is $21.00, about 1.8% above its November 5 closing price of $20.63

• The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 15 three months ago

Press Release: ID:nGNX9PKX1f

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)